Oppenheimer Cuts enGene (NASDAQ:ENGN) Price Target to $30.00

enGene (NASDAQ:ENGN) had its price objective lowered by stock analysts at Oppenheimer from $33.00 to $30.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target would indicate a potential upside of 336.68% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. Citigroup reiterated a “market outperform” rating on shares of enGene in a research note on Monday, January 5th. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of enGene in a research note on Monday. Jefferies Financial Group started coverage on shares of enGene in a report on Friday, January 30th. They set a “buy” rating and a $28.00 target price for the company. Citizens Jmp boosted their target price on shares of enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a research note on Wednesday, November 12th. Finally, Guggenheim reiterated a “buy” rating on shares of enGene in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.86.

enGene Trading Down 1.0%

enGene stock traded down $0.07 during midday trading on Wednesday, reaching $6.87. 580,168 shares of the stock traded hands, compared to its average volume of 418,494. The firm has a market cap of $460.22 million, a PE ratio of -3.06 and a beta of -0.29. enGene has a 12-month low of $2.65 and a 12-month high of $12.25. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.09. The company has a 50-day simple moving average of $9.50 and a two-hundred day simple moving average of $8.11.

enGene (NASDAQ:ENGN) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.11. Research analysts expect that enGene will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of enGene

Several large investors have recently added to or reduced their stakes in ENGN. Cresset Asset Management LLC acquired a new stake in enGene during the second quarter valued at approximately $36,000. Affinity Asset Advisors LLC acquired a new position in shares of enGene during the 2nd quarter worth $280,000. Paloma Partners Management Co bought a new stake in enGene during the second quarter worth approximately $38,000. PFS Partners LLC bought a new position in shares of enGene in the third quarter worth about $61,000. Finally, Raymond James Financial Inc. boosted its position in shares of enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after acquiring an additional 7,932 shares during the period. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.